<DOC>
	<DOCNO>NCT01185704</DOCNO>
	<brief_summary>This randomize open-label study compare in-vitro fertilization/intracytoplasmic sperm injection ( IVF/ICSI ) outcomes two regimen Cetrotide® ( Cetrorelix acetate ) 0.25 milligram ( mg ) use Day 1 Day 7 menstrual cycle ( Day 0 Day 6 stimulation ) polycystic ovarian ( PCO ) woman assist reproductive technology ( ART ) .</brief_summary>
	<brief_title>Analysis Two Therapeutic With Cetrotide® Polycystic Ovarian ( PCO ) Women Assisted Reproductive Technology ( ART )</brief_title>
	<detailed_description>Polycystic ovarian syndrome population androgenic syndrome characterize wide spectrum clinical manifestation obesity , hirsutism , insulin resistance , diabetes presence specific ultrasonic feature . Cetrotide® , cetrorelix acetate , antagonist luteinizing-hormone-releasing hormone ( LHRH ) . Cetrotide® register 70 country ( include France ) prevention premature ovulation subject undergo control ovarian stimulation , follow oocyte pick-up ARTs . Ovitrelle® , active ingredient human chorionic-gonadotropin alfa , administer trigger final follicular maturation luteinization stimulation follicular growth . OBJECTIVES Primary objective : - To compare hormonal level plasmatic estradiol release day ( day r-hCG administration ) induce Cetrotide® 0.25 mg/day start Day 1 ( Group A : Day 1 ) Day 7 ( Group B : Day 7 ) menstrual cycle ( Day 0 ( S0 ) Day 6 ( S6 ) stimulation ) PCO subject undergoing IVF/ICSI procedure . Secondary objective : - To compare hormonal change stimulation induce Cetrotide® A B Groups - To assess ultrasound scan ( US ) follicular development induce Cetrotide® A B Groups - To assess biological clinical outcome induce Cetrotide® A B Groups - To monitor safety Cetrotide A B Groups The trial conduct outpatient basis . Once subject meet eligibility criterion , randomly assign one two treatment group .</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Female subject PCO Polycystic ovary syndrome ( PCOS ) accord revise 2003 Rotterdam Consensus Female subject suitable IVF/ICSI , undergo first second attempt 1835 year old , Body Mass Index ( BMI ) less equal 32 , nonsmoking least Visit 0 ( V0 ) Normal FSH value ( le 10 international unit per liter [ IU/L ] ) Day 3 spontaneous cycle within 12 month prior trial Anti Mullerian Hormone ( AMH ) value ( great 1.5 nanogram per milliliter [ ng/mL ] ) spontaneous cycle within 12 month prior trial least V0 No history active genitourinary infection Normal thyroid function ( adequate substitution least 3 month ) Negative cervical papanicolaou test within last 12 month prior study entry No gonadotropin , least one month prior trial No metformin therapy least one month prior Visit 1 ( V1 ) Subject able participate trial provide write , informed consent . Ongoing pregnancy , pregnancy within 3 month prior study entry , contraindication pregnancy carry pregnancy term Drilling 3 month prior V0 Uterine malformation , diethylstilbestrol syndrome , synechia Female subject World Health Organization ( WHO ) Type I III anovulation Female subject hyperprolactinemia Female subject 2 recurrent miscarriage ( early late , reason ) Known infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B C virus , subject partner Abnormal gynecological bleeding undetermined origin History major thromboembolic disease Endometriosis ( Grade III IV ) Presence history malignant tumor related treatment Known case tumor hypothalamus pituitary gland Clinically significant systemic disease clinically significant abnormal hematology , chemistry , urinalysis result screen Known allergic reaction hypersensitivity Cetrotide® Ovitrelle® Any active substance abuse history drug , medication alcohol abuse past 5 year Participation another clinical trial within 3 month prior study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Cetrorelix acetate ; follitropin alfa ; human chorionic-gonadotropin alfa ; follicular maturation ; pregnancy ; ovarian stimulation</keyword>
</DOC>